🔍

JUBLINGREA - Jubilant Ingrev.

📊 NSE: JUBLINGREA 🏢 Chemicals 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore

🟢 POSITIVE ⭐ 7/10

M&A 📅 13 Mar 2026, 08:18 PM

Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.

Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.
Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.
Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.
Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.
The acquisition is expected to be finalized within an indicative period of 30 days.

💡 Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.

Jubilant Ingrevia Seeks Re-appointment of Independent Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Mar 2026, 08:10 PM

Jubilant Ingrevia Limited has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mrs. Ameeta Chatterjee as an Independent Director. The proposed re-appointment is for a second term of five years, effective from April 17, 2026, to April 16, 2031. Shareholders eligible as of the February 26, 2026, cut-off date can participate in the remote e-voting process. The voting results will be declared on or before April 7, 2026.

Proposal for re-appointment of Mrs. Ameeta Chatterjee as Independent Director for a second 5-year term.
The new term is scheduled to run from April 17, 2026, until April 16, 2031.
Remote e-voting period starts March 6, 2026, and ends April 4, 2026.
The cut-off date for shareholder eligibility to vote was February 26, 2026.
The resolution is being proposed as a Special Resolution requiring requisite majority approval.

💡 This is a routine corporate governance matter regarding board composition. Investors should review the director's profile in the explanatory statement and cast their votes during the e-voting window.

Jubilant Ingrevia receives ₹72.1 Lakh Tax Demand and Penalty for FY 2017-18

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 09 Feb 2026, 04:52 PM

Jubilant Ingrevia Limited has received an order from the Assistant Commissioner of Central GST, Bijnor, confirming a demand for Service Tax on Ocean Freight for the financial year 2017-18. The total demand consists of ₹36.05 lakh in tax and an equivalent penalty of ₹36.05 lakh, plus interest. The company has stated it has a strong case on merits and intends to file an appeal before the Commissioner (Appeals). Management has clarified that this development will not have any material financial or operational impact on the company.

Tax demand of ₹36,04,971 confirmed for FY 2017-18 regarding Ocean Freight
Penalty of ₹36,04,971 imposed by the CGST authorities
Interest charges applicable under Section 75 of the Finance Act, 1994
Company to file an appeal before the Commissioner (Appeals) upon receipt of the certified order
Management confirms no material financial or operational impact on the entity

💡 No immediate action is required as the financial impact is negligible relative to the company's scale. Investors should view this as a routine tax litigation matter.

Jubilant Ingrevia Q3 FY26: 9% Volume Growth, INR 2.5 Interim Dividend, EBITDA at INR 136 Cr

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 04:42 PM

Jubilant Ingrevia reported stable Q3 FY26 revenue of INR 1,051 crore, supported by a 9% year-on-year volume growth that offset softer global pricing. The company declared an interim dividend of 250% (INR 2.5 per share) and highlighted a robust opportunity funnel of over 100 projects with a peak revenue potential of INR 3,500 crore. While quarterly EBITDA dipped 8% to INR 136 crore due to pricing headwinds, the 9-month EBITDA rose 8% to INR 436 crore. Management expects growth to accelerate in Q4 FY26, driven by the commencement of a major CDMO order and new capacity expansions.

Achieved 9% YoY volume growth in Q3 FY26, marking the second-highest volumes in the last 12 quarters.
Declared an interim dividend of 250%, translating to INR 2.5 per equity share.
Specialty Chemicals segment maintained resilient margins above 25% despite intense global pricing pressure.
Secured 16 new molecule wins during the year with an estimated peak revenue potential of INR 1,400 crore.
Renewable energy share increased to 34%, contributing to a 10% YoY reduction in power and fuel expenses.

💡 Investors should focus on the company's transition toward high-margin CDMO and specialty segments, with Q4 FY26 being a critical period for new order execution. The stock is a 'Watch' for signs of recovery in global chemical pricing which could further boost EBITDA margins.

Jubilant Ingrevia Releases Audio Recording of Q3 FY26 Investor Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 07:25 PM

Jubilant Ingrevia Limited has disclosed the audio recording link for its investor conference call held on February 5, 2026. The call addressed the company's unaudited financial performance for the quarter and nine-month period ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording on the company's website to hear management's detailed commentary on business operations and future outlook.

Audio recording for Q3 and 9M FY26 earnings call is now publicly available.
The conference call was conducted on February 5, 2026, following the results announcement.
Filing made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Recording provides access to management's responses to institutional investor queries.

💡 Investors should listen to the recording to understand management's guidance on margins and demand trends in the specialty chemicals sector. No immediate action is required as this is a routine procedural filing.

Jubilant Ingrevia Publishes Q3 & 9M FY26 Financial Results in Newspapers

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 05 Feb 2026, 04:52 PM

Jubilant Ingrevia Limited has published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Board of Directors on February 4, 2026, and subsequently advertised in Financial Express and Hindustan newspapers on February 5, 2026. This filing is a routine regulatory requirement under SEBI (LODR) Regulations to ensure public access to financial performance data. Investors can access the full results via the company's website or the provided QR code in the advertisements.

Board of Directors approved Q3 and nine-month results on February 4, 2026
Results published in Financial Express (English) and Hindustan (Hindi) on February 5, 2026
Filing includes a Quick Response (QR) code for direct digital access to financial statements
Compliance maintained with Regulations 30 and 47 of SEBI (LODR) Regulations, 2015

💡 Investors should review the detailed financial statements on the company website to evaluate the quarterly performance metrics. This is a procedural filing and does not contain new financial data beyond what was previously approved by the board.

Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:48 PM

Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.

Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.
Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.
CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.
The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.
Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.

💡 Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.

Jubilant Ingrevia Q3 FY26: PAT Drops 32% to ₹47 Cr; Declares ₹2.5 Interim Dividend

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:47 PM

Jubilant Ingrevia reported a mixed Q3 FY26 with revenue declining 1% YoY to ₹1,051 crore and PAT falling 32% to ₹47 crore, largely impacted by a one-time exceptional expense related to labor code amendments and global pricing pressures. Despite the bottom-line hit, the company maintained stable EBITDA margins of 13% and declared an interim dividend of ₹2.5 per share. Management highlighted a robust opportunity funnel of over ₹3,500 crore and the upcoming commencement of a major CDMO order in Q4 FY26. Volume growth across Specialty Chemicals and Nutrition segments helped offset softer global pricing.

Revenue for Q3 FY26 stood at ₹1,051 crore, a marginal 1% YoY decline due to global pricing pressures.
EBITDA for the quarter was ₹136 crore with a stable margin of 13%, while 9M FY26 EBITDA rose 8% YoY.
The Board declared an interim dividend of 250% amounting to ₹2.5 per equity share.
Specialty Chemicals segment maintained a strong EBITDA margin of 25% despite pricing volatility in Pyridine.
CDMO pipeline expanded to over 100 opportunities with a peak annual revenue potential of ₹3,500 crore.

💡 Investors should monitor the execution of the major CDMO order starting Q4 FY26 and the stabilization of global chemical pricing. While short-term earnings are under pressure, the strong expansion pipeline and dividend payout offer some support for long-term holders.

Jubilant Ingrevia Declares Interim Dividend of Rs 2.50 Per Share; Record Date Feb 10

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Feb 2026, 07:01 PM

Jubilant Ingrevia Limited has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. This dividend is applicable to shares with a face value of Re 1 each. The company has designated February 10, 2026, as the record date for identifying eligible shareholders. Shareholders can expect the dividend payment or dispatch to occur on or before March 4, 2026.

Interim dividend of Rs 2.50 per equity share (250% of face value).
Record date for dividend eligibility set for February 10, 2026.
Dividend payment to be completed on or before March 4, 2026.
Board meeting concluded on February 4, 2026, to approve the payout.

💡 Existing shareholders should ensure they hold the stock before the ex-dividend date to qualify for the Rs 2.50 payout. New investors may consider the dividend yield relative to the current stock price.

Jubilant Ingrevia Declares ₹2.50 Interim Dividend and Re-appoints Independent Director

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Feb 2026, 05:44 PM

Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26, representing a 250% payout on the face value of ₹1. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 17, 2026. This dual announcement reflects a commitment to both shareholder returns and leadership continuity.

Interim dividend of ₹2.50 per equity share of ₹1 face value declared for FY 2025-26
Record date for dividend eligibility set for February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, with all items approved

💡 Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the February 10 record date. The re-appointment of an experienced director like Ms. Chatterjee is a positive sign for corporate governance stability.

Jubilant Ingrevia Declares ₹2.50 Interim Dividend; Sets Feb 10 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Feb 2026, 05:42 PM

Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to shareholders on or before March 4, 2026.

Interim dividend declared at ₹2.50 per equity share of face value ₹1 each
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Re-appointment of Ms. Ameeta Chatterjee as Independent Director for a 5-year term until April 2031

💡 Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the Feb 10 record date. The re-appointment of an experienced independent director signals management stability.

Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Sets Feb 10 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Feb 2026, 05:40 PM

Jubilant Ingrevia has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board has approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to eligible shareholders by March 4, 2026.

Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded at 5:15 PM on February 4, 2026

💡 Investors looking to benefit from the dividend should ensure they hold the stock before the ex-dividend date. The re-appointment of an experienced independent director provides continuity in corporate governance.

Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Re-appoints Independent Director

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Feb 2026, 05:37 PM

Jubilant Ingrevia's Board has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to identify eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. This dual announcement highlights both a commitment to shareholder returns and leadership continuity.

Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, at 05:15 p.m.

💡 Investors interested in the dividend should ensure they hold the stock before the record date of February 10, 2026. The re-appointment of an experienced director is a positive sign for corporate governance stability.

Jubilant Ingrevia Q3 FY26 Net Profit Dips 5.6% YoY to ₹65.4 Crore; Revenue Flat

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 05:32 PM

Jubilant Ingrevia reported a consolidated net profit of ₹65.41 crore for Q3 FY26, a 5.6% decline from ₹69.30 crore in the same quarter last year. Revenue from operations remained stagnant at ₹1,050.99 crore compared to ₹1,056.77 crore YoY. Sequentially, the company saw a 6.2% drop in revenue and a 5.8% decline in profit compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains stronger than the previous year, with PAT up 21% at ₹209.65 crore.

Consolidated Net Profit for Q3 FY26 stood at ₹65.41 crore vs ₹69.30 crore YoY.
Total Revenue from operations was ₹1,050.99 crore, showing a marginal decline of 0.5% YoY.
Nutrition & Health Solutions segment grew by 5.9% YoY to ₹200.76 crore.
Speciality Chemicals segment revenue declined slightly to ₹457.57 crore from ₹467.64 crore YoY.
Nine-month (9M FY26) PAT increased significantly to ₹209.65 crore from ₹172.90 crore in 9M FY25.

💡 The quarterly results indicate a temporary slowdown in the Speciality Chemicals and Intermediates segments. Investors should hold for long-term recovery while monitoring global chemical pricing trends and margin stability.

Jubilant Ingrevia to Participate in Nuvama India Conference 2026 on Feb 9-10

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 04:19 PM

Jubilant Ingrevia Limited has scheduled its participation in the Nuvama India Conference 2026 to be held in Mumbai. The management will interact with institutional investors and analysts on February 9th and 10th, 2026, between 10:00 am and 5:00 pm. These interactions will include both group and one-on-one meetings conducted in person. The company has clarified that no unpublished price sensitive information (UPSI) will be discussed during these sessions.

Participation in the Nuvama India Conference 2026 scheduled for February 9-10, 2026.
Meetings to be held at Grand Hyatt, Mumbai, from 10:00 am to 5:00 pm.
Interaction format includes both group and one-on-one meetings with investors.
Discussions will be restricted to generally available information as per SEBI regulations.

💡 This is a routine investor outreach event; existing shareholders should look for any subsequent investor presentations or transcripts that may provide updates on the company's growth outlook.

View All JUBLINGREA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Specialty Chemicals (SC) grew 15% YoY in FY25 to INR 1,818 Cr and 12% YoY in Q2 FY26. Nutrition & Health Solutions (NHS) reported INR 181 Cr in Q2 FY26, a 1% QoQ increase but 1% YoY decline. Chemical Intermediates (CI) achieved its highest quarterly revenue in 6 quarters in Q2 FY26 despite pricing pressures.

Geographic Revenue Split

Domestic India accounts for 53% of revenue. International markets contribute 47%, with Europe and Japan at 29%, and China/Rest of World at 18%. US revenue grew significantly by 52% YoY in FY25.

Profitability Margins

Standalone Profit After Tax (PAT) was INR 251.2 Cr in FY25, up 37% YoY with a 6.0% margin. Q2 FY26 PAT grew 18% YoY to INR 70 Cr. Operating margins are expected to sustain at 13-15% over the medium term as the product mix shifts toward higher-margin SC and NHS segments.

EBITDA Margin

Consolidated EBITDA margin improved to 12.4% in FY25 from 10.2% in FY24. Specialty Chemicals achieved a record 27% margin in Q4 FY25 and maintained 26% in Q2 FY26. Overall EBITDA grew 8% YoY in Q2 FY26 and 18% in H1 FY26.

Capital Expenditure

The company incurred INR 1,800 Cr in capex between FY22 and FY25. Planned capex for FY26 is approximately INR 600 Cr, primarily for the CDMO Agro plant at Bharuch and a new multipurpose facility at Gajraula.

Credit Rating & Borrowing

Crisil reaffirmed 'Crisil A1+' for commercial paper. India Ratings affirmed 'IND AA+/Stable/IND A1+' for bank loan facilities of INR 2,388.38 Cr. Interest coverage ratio improved to ~10 times in FY25 from 8.67 times in FY24.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (for Acetyls/CI segment), Pyridine, and Picolines. The company is significantly backwards integrated in Pyridine and Picolines, which supports its cost leadership in Specialty Chemicals.

Import Sources

China is mentioned as a historical source and a competitor region; the company has de-risked its Pyridine exposure to China by entering other geographies like Europe and Japan.

Capacity Expansion

Groundbreaking of a new Multi-Purpose Plant (MPP) in Gajraula is underway with completion expected by late 2026. A new CDMO Agro plant is also being commissioned at Bharuch to serve a major USD 300M+ contract.

Raw Material Costs

Raw material costs are impacted by global pricing volatility; however, vertical integration in Pyridine and Acetyls helps mitigate these fluctuations. Lean 1.0 initiatives delivered INR 120 Cr in annualised savings.

Manufacturing Efficiency

Lean 2.0 has been launched to deliver an additional INR 100 Cr+ in annualised cost savings in FY26. The company focuses on digitising operations to maintain cost leadership.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

The 'Pinnacle 345' plan aims to triple revenue and quadruple EBITDA in 5 years. This will be achieved through a USD 300M+ 5-year CDMO contract starting in early 2026, entry into high-tech semiconductor chemicals with a new R&D facility in Greater Noida, and expanding Diketene derivative capacities.

Products & Services

Pyridine, Picolines, Diketene derivatives, Acetic Anhydride, Ethyl Acetate, Vitamin B3 (Niacinamide), Choline Chloride, and CDMO services for agrochemical and pharmaceutical innovators.

New Products/Services

New product launches include high-purity semiconductor chemicals and expanded human nutrition solutions. The CDMO segment has a funnel of 100+ new opportunities.

Market Expansion

Targeting increased export share (currently 47%) and deeper penetration in the US market, which saw 52% growth in FY25. Entry into the semiconductor innovation space via the Greater Noida R&D facility.

Market Share & Ranking

Global leadership in pyridine derivatives and a leading market position across most core products.

Strategic Alliances

Signed a USD 300+ million, five-year CDMO contract with a leading multinational agrochemical innovator.

🌍 External Factors

Industry Trends

The industry is seeing a steady recovery in volumes but pricing remains under pressure. There is a shift toward sustainable 'green' chemical variants and increased outsourcing to CDMOs (market projected to reach USD 319.6 billion by 2029).

Competitive Landscape

Competes with global players and Chinese manufacturers. European competitors are currently disadvantaged by elevated energy costs and weaker demand.

Competitive Moat

Moat is built on deep vertical integration (Pyridine/Acetyls), cost leadership through Lean initiatives, and high switching costs in the CDMO segment due to regulatory and technical complexity.